In November 2020, a seemingly innocuous symptom sent shockwaves through Alla Feldbeyn’s life — unexpected vaginal bleeding, a red flag for women, especially those who have already navigated the trials of menopause. This alarming sign led to a diagnosis of Stage 1 endometrial cancer, a disease that has seen a disturbing rise in incidence across the United States over the past two decades. Contributing factors include increasing obesity rates and an aging population, making awareness of such symptoms more critical than ever.
Initially, after undergoing a hysterectomy, Feldbeyn was reassured by her medical team that she would not require further treatments like chemotherapy or radiation. However, her peace was shattered in 2022 when she began experiencing persistent coughing and unusual side pain. What she initially suspected to be gallbladder issues turned out to be something far graver — red spots on her lungs, indicating that her cancer had progressed to Stage 4.
Feldbeyn faced a challenging medical landscape, where her initial doctor dismissed the possibility of her endometrial cancer returning, instead suggesting a different type of cancer altogether. This scenario highlights a critical issue in cancer care — the necessity for timely intervention and accurate diagnosis. Frustrated by delayed appointments and unsatisfactory answers, she sought a second opinion from Dr. Brian Slomovitz, director of gynecologic oncology at Mount Sinai Medical Center in Miami. The difference was remarkable; just days after her first visit, she began chemotherapy.
The journey from Stage 1 to Stage 4 was not just a testament to the aggressive nature of her illness but also to the complexities surrounding cancer treatment. After undergoing lung surgery and chemotherapy, Feldbeyn enrolled in a clinical trial assessing the drug selinexor, an oral medication typically used for certain blood cancers. However, as often happens in clinical trials, the treatment was not effective for her, leading to her withdrawal in October 2023.
Undeterred, Feldbeyn joined another clinical trial focusing on non-chemotherapeutic approaches to treat endometrial cancer. Dr. Slomovitz emphasized the evolving landscape of cancer treatment, stating, “In the past, hormonal therapy by itself has been used for the treatment of this disease. However, the response rates are relatively low, and the duration of response is only a couple of months.” This shift towards combination therapies combining anti-hormonal and targeted treatments is a promising avenue for more personalized care, addressing the unique cellular characteristics of each patient’s cancer.
Feldbeyn’s current regimen includes daily doses of letrozole and thrice-monthly infusions of Nab-sirolimus, a drug yet to be extensively studied in women with endometrial cancer. This innovative delivery system aims to enhance drug effectiveness while minimizing severe side effects. Despite experiencing challenges such as nosebleeds and fatigue, Feldbeyn has maintained a positive outlook and continues to work remotely in her role as a senior director for a program serving developmentally disabled adults.
Dr. Slomovitz noted, “The great news about Alla is not only her response to the therapy, but she’s definitely maintaining her quality of life.” This holistic perspective on treatment is vital, as many patients often grapple with the physical and emotional toll of ongoing cancer care. Feldbeyn’s adventurous spirit shines through her love for travel, where she and her husband indulge in cruises and memorable trips — a testament to her resilience.
Feldbeyn has become an advocate for proactive health management, encouraging others to seek second opinions and consider clinical trial participation. Alarmingly, only about 7% of adults with cancer in the U.S. opt to enroll in clinical trials each year. This statistic underscores the need for greater awareness and outreach, ensuring that diverse populations have access to the latest advancements in cancer treatment.
Dr. Slomovitz highlighted the importance of recognizing warning signs, particularly for women experiencing abnormal bleeding post-menopause. “Just one spot of blood should prompt a visit to the doctor,” he advised. Additional symptoms, including pelvic or stomach pain, urinary discomfort, and abnormal vaginal discharge, should never be ignored.
As Feldbeyn continues her fight against cancer, her journey serves as a powerful reminder of the importance of vigilance, advocacy, and the pursuit of treatment options that prioritize both efficacy and quality of life. In navigating the complexities of cancer care, her story provides hope and encouragement for others facing similar battles.
